Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
ANTIGEN-SCREENING SYSTEM - Perfecting the Promise of T Cell Therapies for Infectious Disease & Cancer
THE EVOLUTION OF IMMUNOTHERAPIES The human body is armed with an efficient and elegant immune system that fights pathogens and...SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing: Biologics Present a New Set of Challenges
Contributor Cindy H. Dubin speaks with leading syringe developers and contract manufacturers to discuss how they are overcoming industry challenges and provides a look at some of the innovative advancements in prefilled syringe technology.
NANOPARTICLE CHARACTERIZATION - One Size Does Not Fit All: Nanoparticle Size Analysis for Nanomedicine Applications
Andrew N. Cleland, PhD, Jean-Luc Fraikin, PhD, Peter Meinhold, PhD, and Franklin Monzon, PhD, describe a new diagnostic instrument able to rapidly and accurately report detailed nanoparticle size distributions for a wide variety of nanoparticle types and concentrations in a range of different solutions.
LIPID NANOPARTICLES - EnCore(TM): Facilitating Delivery of RNAi Therapeutics to Treat Cancer
Marc T. Abrams, PhD, and Bob D. Brown, PhD, explain how nanoparticle technology has the potential to enable tumor bioavailability even in the absence of a targeting ligand.
VBI Vaccines Announces Vaccine Stability Collaboration With GlaxoSmithKline
VBI Vaccines Inc. has entered into a research collaboration with GlaxoSmithKline Biologicals SAto evaluate VBI’s LPV Platform, a proprietary formulation...Enable Injections & Flex Partner for Production of Wearable High-Volume Injectors
Enable Injections Inc. recently announced it has entered into a product development and manufacturing partnership with Flex. As part of...ADVANCED DELIVERY DEVICES - How Data Hubs & Smart Devices Are Enabling the Rise of Therapeutic Ecosystems
Stephen Allan discusses how unique collaborations between tech and biotech reflect a new paradigm in how therapeutics are being commercialized and marketed under the new pay-for-performance healthcare model.
Egalet Submits NDA for Morphine Sulfate ER Tablets
Egalet Corporation recently announced the company has submitted an NDA for ARYMO ER (morphine sulfate) extended-release tablets for the management...Soligenix Announces Initiation of Pivotal Phase III Clinical Trial
Soligenix, Inc. recently announced that patient enrollment has been opened for its Phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating...Aptar Pharma Presents a Step Change in the Performance of DF30Plus for PMDIs Incorporating COC
Aptar Pharma, a global solution provider of innovative and proven aerosol, injection, and spray delivery systems for biotech, healthcare, and...
